Interim results from an ongoing phase 1/2 open-label study evaluated povetacicept in adults with IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). Among 54 participants with IgAN, treatment was associated with substantial reductions in proteinuria at 48 weeks—64% in the 80-mg cohort and 56% in the 240-mg cohort—while eGFR remained stable. Hematuria resolved in 90% and 94% of evaluable participants, respectively, and clinical remission was achieved in 53% of those receiving 80 mg and 34% receiving 240 mg.
The smaller pMN cohort also showed reductions in proteinuria and stable kidney function, although the limited number of participants makes those findings preliminary. Across cohorts, most adverse events were mild or moderate, no serious adverse events were considered related to treatment, and several cases of severe hypogammaglobulinemia were reported. Because the study was open-label, uncontrolled, and not powered for statistical comparisons, the findings should be considered early evidence. Phase 3 trials are underway to further evaluate efficacy and safety in IgAN and pMN.
Reference: Madan A, Yalavarthy R, Kim DK, et al. Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy. Kidney Int Rep. 2025 Nov 3;11(1):106-116. doi: 10.1016/j.ekir.2025.10.029.
